|Globalization drives innovation
Globalization is the most prominent feature of science and innovation in the early 21st century, according to Research & Innovation Performance of the G 20.Thomson Reuters ScienceWatch. Today, it’s not just the US which is pouring money into R&D. Actually the pouring is now more of a drip, drip, drip. The total US spend has remained level in recent years. Not surprising, China has increased R&D spending from 5.5% in 2003 to 14% in 2012, whereas that of the US has fallen from 33% to 27.% over the same period.
Worldwide, the number of pharmaceutical firms electing to adopt the LDTD has increased this year, and R&D acceleration has resulted as well.
Innovative use of LDTD at biotech and pharmaceutical firms worldwide can be found early on during ADME screening, whereby more compounds are analyzed in less time, seeking to compress the drug discovery process, shaving time (like years) and money (like hundreds of millions of dollars) off of the entire drug discovery and development to commercialization process.
Furthermore, R&D globally occurs through alliances and partnership collaborations. Collaboration is underway in technology innovation too, since the value of mass spectrometry improves when coupled with LDTD.
Novartis found sample analysis run time of 10 seconds achieved using LDTD-APCI-MS/MS vs. 4.5 minutes for the current validated method (LC-ESI-MS/MS). Other firms report their findings at LDTD.
|Questions? Want to learn more? Make arrangements by contacting Richard Halpern email@example.com, or call 617-364-7683, or Contact Us.|